Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

被引:14
|
作者
Topp, Max S. [1 ]
Stein, Anthony S. [2 ]
Goekbuget, Nicola [3 ]
Horst, Heinz-August [4 ]
Boissel, Nicolas [5 ]
Martinelli, Giovanni [6 ]
Kantarjian, Hagop [7 ]
Brueggemann, Monika [8 ]
Chen, Yuqi [9 ]
Zugmaier, Gerhard [10 ]
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] City Hope Med Ctr, Gehr Leukemia Ctr, Duarte, CA USA
[3] Univ Klinikum, Med Klin Hamatol Onkol Rheumatol Infektiol 3, Frankfurt, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Innere Med 2, Kiel, Germany
[5] Hop St Louis, Unite Hematol Adolescents & Jeunes Adultes, Paris, France
[6] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Sci Directorate, Meldola, FC, Italy
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[8] Univ Klinikum Schleswig Holstein, Sekt Hamatol Spezialdiagnost, Klin Innere Med 2, Kiel, Germany
[9] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[10] Amgen Res Munich GmbH, Global Dev, Munich, Germany
来源
CANCER MEDICINE | 2021年 / 10卷 / 08期
关键词
acute lymphoblastic leukemia; BiTE® blinatumomab; salvage; stem cell transplant;
D O I
10.1002/cam4.3731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Blinatumomab is a BiTE(R) immuno-oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in patients with r/r BCP ALL. Patient-level pooled data were used for this analysis. In total, 532 adults with r/r BCP ALL treated with blinatumomab were included (first salvage, n = 165; second or later salvage, n = 367). Compared with patients who received blinatumomab as second or later salvage, those who received blinatumomab as first salvage had a longer median overall survival (OS; 10.4 vs. 5.7 months; HR, 1.58; 95% CI, 1.26-1.97; P < .001) and relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ratio, 0.59; 95% CI, 0.41-0.85; P = .005), minimal residual disease response (n = 68 [41%] vs. n = 118 [32%]), and allogeneic hematopoietic stem cell transplant (alloHSCT) realization (n = 60 [36%] vs. n = 88 [24%]), and alloHSCT in continuous remission (n = 33 [20%] vs. n = 52 (14%]). In a subgroup analysis, there was no apparent effect of prior alloHSCT on median OS in either salvage group. The safety profile of blinatumomab was generally similar between the groups; however, cytokine release syndrome, febrile neutropenia, and infection were more frequent with second or later salvage than with first salvage. In this pooled analysis, the logistic regression analyses indicated greater benefit with blinatumomab as first salvage than as second or later salvage, as evident by the longer median OS, longer median RFS, and higher rates of remission. Overall, blinatumomab was beneficial as first salvage and as second or later salvage, but the effects were favorable as first salvage. Aims Materials & Methods Results Discussion Conclusion
引用
收藏
页码:2601 / 2610
页数:10
相关论文
共 50 条
  • [11] Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Stein, Anthony
    Franklin, Janet L.
    Chia, Victoria M.
    Arrindell, Deborah
    Kormany, William
    Wright, Jacqueline
    Parson, Mandy
    Amouzadeh, Hamid R.
    Choudhry, Jessica
    Joseph, Guiandre
    DRUG SAFETY, 2019, 42 (05) : 587 - 601
  • [12] Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Gore, Lia
    Locatelli, Franco
    Zugmaier, Gerhard
    Handgretinger, Rupert
    O'Brien, Maureen M.
    Bader, Peter
    Bhojwani, Deepa
    Schlegel, Paul-Gerhardt
    Tuglus, Catherine A.
    von Stackelberg, Arend
    BLOOD CANCER JOURNAL, 2018, 8
  • [13] Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Lia Gore
    Franco Locatelli
    Gerhard Zugmaier
    Rupert Handgretinger
    Maureen M. O’Brien
    Peter Bader
    Deepa Bhojwani
    Paul-Gerhardt Schlegel
    Catherine A. Tuglus
    Arend von Stackelberg
    Blood Cancer Journal, 8
  • [14] Blinatumomab: A ray of hope for relapsed/refractory adult B-cell acute lymphoblastic leukemia
    Kapoor, Akhil
    Rajput, Prakash Singh
    Beniwal, Surender
    Kumar, Harvindra Singh
    CLINICAL CANCER INVESTIGATION JOURNAL, 2014, 3 (06): : 577 - 578
  • [15] Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Folan, Stephanie A.
    Rexwinkle, Amber
    Autry, Jane
    Bryan, Jeffrey C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S2 - S5
  • [16] Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Gore, Lia
    Locatelli, Franco
    Zugmaier, Gerhard
    Zwaan, Christian M.
    Bhojwani, Deepa
    Handgretinger, Rupert
    Bader, Peter
    O'Brien, Maureen M.
    Trippett, Tanya M.
    Brethon, Benoit
    Rizzari, Carmelo
    DuBois, Steven G.
    Schlegel, Paul Gerhardt
    Barnette, Phillip
    Messina, Chiara
    Hu, Kuolung
    Mergen, Noemi
    Fischer, Anja
    Whitlock, James
    von Stackelberg, Arend
    BLOOD, 2014, 124 (21)
  • [17] Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Rambaldi, Alessandro
    Huguet, Francoise
    Zak, Pavel
    Cannell, Paul
    Tran, Qui
    Franklin, Janet
    Topp, Max S.
    BLOOD ADVANCES, 2020, 4 (07) : 1518 - 1525
  • [18] Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Zugmaier, Gerhard
    Brueggemann, Monika
    Wood, Brent L.
    Horst, Heinz A.
    Zeng, Yi
    Martinelli, Giovanni
    CANCERS, 2021, 13 (22)
  • [19] A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    von Stackelberd, Arend
    Zugmaier, Gerhard
    Handgretinger, Rupert
    Locatelli, Franco
    Rizzari, Carmelo
    Trippett, Tanya M.
    Borkhardt, Arndt
    Rheingold, Susan R.
    Bader, Peter
    Bhojwani, Deepa
    Cooper, Todd Michael
    DuBois, Steven G.
    O'Brien, Maureen M.
    Zwaan, Christian M.
    Holland, Chris
    Mergen, Noemi
    Fischer, Anja
    Zhu, Min
    Hijazi, Youssef
    Whitlock, James
    Gore, Lia
    BLOOD, 2013, 122 (21)
  • [20] A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Horibe, Keizo
    Morris, Joan D.
    Tuglus, Catherine A.
    Dos Santos, Cedric
    Kalabus, James
    Anderson, Abraham
    Goto, Hiroaki
    Ogawa, Chitose
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (02) : 223 - 233